3 Pharma Formulation, Specialty Glycol and Basmati Rice Stocks With a Strong Future Roadmap: FDC, India Glycols and LT Foods

Pharma formulation, specialty glycol and basmati rice stocks give investors exposure to health products, chemicals and food staples sold at home and abroad. Volumes, pricing and input costs decide how much of that demand turns into profit.

Readers comparing pharma formulation, specialty glycol and basmati rice stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.

This list covers three pharma formulation, specialty glycol and basmati rice stocks: FDC for oral rehydration products such as Electral along with eye, ear and anti-infective formulations, India Glycols for glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and LT Foods for basmati and other rice products sold under well-known consumer brands and to export markets. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma Formulation, Specialty Glycol and Basmati Rice Stocks?

Pharma formulation, specialty glycol and basmati rice stocks are shares of companies that make health products, chemicals or packaged food. Results depend on volumes, pricing and input costs, so margins and cash flow separate the stronger names.

Pharma Formulation, Specialty Glycol and Basmati Rice Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three pharma formulation, specialty glycol and basmati rice stocks as of the 14 Oct 2026 close.

Among healthcare and chemicals stocks, all three trade at a discount to their industry P/E multiples.

Why Do Pharma Formulation, Specialty Glycol and Basmati Rice Stocks Have a Strong Roadmap in India?

Pharma formulation, specialty glycol and basmati rice stocks have a strong roadmap in India because health product use, ethanol blending and global demand for basmati keep adding volumes for these firms. Three drivers stand out.

• Health products: Oral rehydration and eye care products see steady demand.
• Renewable chemicals: Ethanol and bio-based chemicals gain policy support.
• Rice exports: Global buyers prefer basmati varieties.

FDC: Established Brands Drive the Pipeline

FDC's roadmap rests on oral rehydration products such as Electral along with eye, ear and anti-infective formulations, with established brands supporting steady sales.

Revenue grew from Rs 1,604.01 crore in FY22 to Rs 2,284.45 crore in FY26, a 42.4% rise, and FY26 revenue was 3.9% higher than FY25. FY26 net profit rose 5.5% to Rs 281.42 crore. Over four years, net profit rose from Rs 216.16 crore in FY22 to Rs 281.42 crore. In Q1 FY27, revenue grew 4.6% to Rs 715.35 crore, and net profit rose 9.2% to Rs 132.49 crore. Operating margin was 20.21% in FY26 and 28.56% in Q1 FY27 against 27.12% a year earlier.

Debt to equity is 0.01 and return on equity is 11.32%. FY26 operating cash flow was Rs 200.45 crore against capital expenditure of Rs 186.56 crore. FDC paid a dividend of Rs 5 per share for FY26, a yield of 1.54%. At a P/E of 18.05 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 28.56% against 20.21% for FY26, so margin stability is the figure to follow as volumes grow.

India Glycols: Green Chemicals and Ethanol Build the Next Leg

India Glycols' roadmap rests on glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock, with ethanol blending and chemical demand supporting volumes.

Revenue grew from Rs 2,889.84 crore in FY22 to Rs 4,216.34 crore in FY26, a 45.9% rise, and FY26 revenue was 11.5% higher than FY25. FY26 net profit rose 26.8% to Rs 292.76 crore. In Q1 FY27, revenue grew 19.3% to Rs 2,988.82 crore, and net profit rose 32.2% to Rs 96.83 crore. Operating margin was 7.12% in FY26.

Debt to equity is 0.58 and return on equity is 9.98%. FY26 operating cash flow was Rs 769.16 crore against capital expenditure of Rs 823.48 crore. India Glycols paid a dividend of Rs 7.5 per share for FY26, a yield of 2.10%. At a P/E of 7.58 against an industry P/E of 54.53, the stock trades below its industry multiple.

What to watch: The P/E of 7.58 against an industry P/E of 54.53 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

LT Foods: Basmati and Packaged Foods Anchor the Roadmap

LT Foods' roadmap rests on basmati rice and packaged foods sold under brands such as Daawat, with exports and branded sales supporting revenue.

Revenue grew from Rs 5,450.58 crore in FY22 to Rs 11,023.06 crore in FY26, a 102.2% rise, and FY26 revenue was 25.7% higher than FY25. FY26 net profit rose 2.2% to Rs 625.38 crore. Over four years, net profit rose from Rs 309.20 crore in FY22 to Rs 625.38 crore. In Q1 FY27, revenue grew 26.4% to Rs 3,161.29 crore, and net profit rose 8.9% to Rs 183.45 crore. Operating margin was 11.35% in FY26.

Debt to equity is 0.36 and return on equity is 13.83%. FY26 operating cash flow was Rs 910.50 crore against capital expenditure of Rs 359.62 crore. LT Foods paid a dividend of Rs 3 per share for FY26, a yield of 0.74%. At a P/E of 21.98 against an industry P/E of 34.85, the stock trades below its industry multiple.

What to watch: The P/E of 21.98 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Best Pharma Formulation, Specialty Glycol and Basmati Rice Stocks in India: FDC vs India Glycols vs LT Foods on Key Financials

Among the best pharma formulation, specialty glycol and basmati rice stocks in India, FDC leads on FY26 operating margin and the lowest debt to equity; India Glycols leads on Q1 FY27 net profit growth and FY26 net profit growth; LT Foods leads on FY26 revenue growth and Q1 FY27 revenue growth. The table puts the numbers side by side.

Healthcare, chemicals and food earnings follow volumes, pricing and input costs, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Pharma Formulation, Specialty Glycol and Basmati Rice Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen pharma formulation, specialty glycol and basmati rice stocks and shortlist pharma formulation, specialty glycol and basmati rice stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check operating margin, debt and cash flow together.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these pharma formulation, specialty glycol and basmati rice stocks

Risks to Consider Before Investing in Pharma Formulation, Specialty Glycol and Basmati Rice Stocks

• Input costs: Changes in raw material prices can affect margins.
• Seasonal demand: Weather and crop cycles can shift sales between quarters.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track FDC, India Glycols and LT Foods live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare and chemicals stocks cover pharma formulations, specialty chemicals and basmati rice. FDC leads on FY26 operating margin and the lowest debt to equity; India Glycols leads on Q1 FY27 net profit growth and FY26 net profit growth; LT Foods leads on FY26 revenue growth and Q1 FY27 revenue growth.

Across pharma formulation, specialty glycol and basmati rice stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pharma formulation, specialty glycol and basmati rice stocks to buy discussed here.

FAQs on Pharma Formulation, Specialty Glycol and Basmati Rice Stocks

Which are the best pharma formulation, specialty glycol and basmati rice stocks in India with a strong roadmap?

Ans. FDC, India Glycols and LT Foods stand out for their roadmaps in pharma formulations, specialty chemicals and basmati rice. FY26 revenue growth was 3.9% at FDC, 11.5% at India Glycols and 25.7% at LT Foods, and return on equity ranges from 9.98% to 13.83%.

Is FDC a good stock to buy now?

Ans. FDC has a debt to equity ratio of 0.01, a return on equity of 11.32% and a P/E of 18.05 against an industry P/E of 37.59. Valuation, input costs and seasonal demand move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of FDC, India Glycols and LT Foods?

Ans. The P/E ratio is 18.05 for FDC (industry 37.59), 7.58 for India Glycols (industry 54.53) and 21.98 for LT Foods (industry 34.85). All of them trade below the industry multiple.

Which of these pharma formulation, specialty glycol and basmati rice stocks has the highest return on equity?

Ans. LT Foods has the highest return on equity at 13.83%, followed by FDC at 11.32% and India Glycols at 9.98%.

What are the risks of investing in pharma formulation, specialty glycol and basmati rice stocks?

Ans. The main risks are input costs, seasonal demand and quarterly trends. Changes in raw material prices can affect margins.

How did FDC, India Glycols and LT Foods perform in Q1 FY27?

Ans. FDC reported revenue of Rs 715.35 crore, up 4.6% year on year, and net profit rose 9.2% to Rs 132.49 crore. India Glycols reported revenue of Rs 2,988.82 crore, up 19.3% year on year, and net profit rose 32.2% to Rs 96.83 crore. LT Foods reported revenue of Rs 3,161.29 crore, up 26.4% year on year, and net profit rose 8.9% to Rs 183.45 crore.

Do pharma formulation, specialty glycol and basmati rice stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 1.54% for FDC, 2.10% for India Glycols and 0.74% for LT Foods, based on dividends declared for FY26.

How can I invest in pharma formulation, specialty glycol and basmati rice stocks in India?

Ans. You can buy pharma formulation, specialty glycol and basmati rice stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.